By Fineline Cube Akeso, Inc. (HKG: 9926) and Shanghai Allink Biotherapeutics Inc. announced a clinical research collaboration to advance a novel combination therapy for locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). China’s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) approval for the Phase II study evaluating Ivonescimab (PD-1/VEGF bispecific antibody) in combination with ALK201 (FGFR2b-targeted antibody-drug conjugate) as first-line treatment.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agencies | NMPA (China) |
| Approval Type | IND approval for Phase II clinical trial |
| Combination Therapy | Ivonescimab + ALK201 |
| Indication | First-line treatment of locally advanced or metastatic sqNSCLC |
| Trial Phase | Phase II |
| Sponsor | Allink Biotherapeutics (full responsibility for execution) |
Drug Profile & Mechanism of Action
- Ivonescimab (AK112): Globally first-in-class PD-1/VEGF bispecific antibody developed by Akeso, simultaneously blocking immune checkpoint inhibition and angiogenesis pathways
- ALK201: FGFR2b-targeted antibody-drug conjugate (ADC) developed by Allink Biotherapeutics, delivering cytotoxic payload specifically to FGFR2b-expressing tumor cells
- Innovation: First combination of a PD-1/VEGF bispecific antibody with an FGFR2b-targeted ADC, designed to overcome treatment resistance through dual complementary mechanisms
- Intellectual Property: Global patents held by respective companies covering molecular structures and combination methodology
Clinical Rationale & Unmet Need
Squamous NSCLC represents approximately 25-30% of all NSCLC cases and remains challenging to treat, particularly in patients without actionable driver mutations. Current first-line options are limited primarily to immunotherapy combinations with modest survival benefits. The dual-target approach combines:
- Immune-oncology enhancement through PD-1 blockade
- Anti-angiogenic effects via VEGF inhibition
- Targeted cytotoxic delivery through FGFR2b-specific ADC
This multi-pronged strategy aims to improve response rates and duration while potentially overcoming primary and acquired resistance mechanisms commonly observed with single-agent approaches.
Strategic Implications
- For Akeso: Expands Ivonescimab’s clinical development beyond existing monotherapy and combination programs, creating additional partnership opportunities
- For Allink Biotherapeutics: Validates FGFR2b as a viable target in sqNSCLC and accelerates ALK201 development through strategic alliance with established biopharmaceutical company
- Market Opportunity: Addresses significant unmet need in ~200,000 annual sqNSCLC cases in China alone, with potential global applicability
Next Steps
- Trial Initiation: Patient enrollment expected to commence within Q3 2026
- Primary Endpoints: Safety, tolerability, objective response rate (ORR), and progression-free survival (PFS)
- Geographic Scope: Initial focus on Chinese sites with potential expansion to international locations based on early data
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and strategic partnerships. Actual results may differ due to risks including trial execution challenges, safety findings, and competitive dynamics in the oncology space.-Fineline Info & Tech